Table 2.
Organ involvement at cohort entry stratified for sex
| 2010–2013 | 2014–2017 | 2018–2021 | ||||
| Female N=195 |
Male N=34 |
Female N=157 |
Male N=50 |
Female N=157 |
Male N=50 |
|
| RP duration, months | 121 (43–244) | 106 (44–231) | 118 (26–238) | 34 (7–168) | 96 (29–239) | 33 (9–81) |
| Non-RP duration, months | 46 (17–127) | 40 (9–143) | 21 (7–115) | 13 (3–88) | 18 (6–73) | 13 (5–36) |
| Diagnosis duration, months | 22 (7–99) | 14 (3–108) | 11 (2–65) | 3 (0–32) | 5 (0–21) | 3 (0–10) |
| Anticentromere antibodies | 82 (42) | 6 (18) | 76 (49) | 11 (22) | 89 (57) | 11 (22) |
| Antitopoisomerase antibodies | 42 (22) | 11 (32) | 28 (18) | 21 (42) | 20 (13) | 16 (33) |
| Disease subset: | ||||||
| Non-cutaneous | 39 (20) | 4 (12) | 44 (28) | 6 (12) | 40 (25) | 3 (6) |
| Limited cutaneous | 125 (64) | 19 (56) | 85 (54) | 24 (48) | 100 (64) | 30 (60) |
| Diffuse cutaneous | 31 (16) | 11 (32) | 28 (18) | 20 (40) | 17 (11) | 17 (34) |
| Pulmonary arterial hypertension | 7 (4) | 1 (3) | 4 (3) | 1 (2) | 5 (3) | 1 (2) |
| Cardiac involvement | 7 (4) | 4 (12) | 6 (4) | 6 (12) | 17 (11) | 8 (16) |
| Interstitial lung disease on HRCT | 83 (43) | 16 (47) | 45 (29) | 20 (40) | 43 (27) | 21 (42) |
| Interstitial lung disease on HRCT and FVC <80% | 18 (9) | 9 (27) | 15 (10) | 5 (10) | 5 (3) | 7 (14) |
| Gastrointestinal involvement | 41 (21) | 15 (44) | 37 (24) | 18 (36) | 26 (17) | 20 (40) |
| Renal crisis | 4 (2) | 1 (3) | 2 (1) | 1 (2) | 5 (4) | – |
| Musculoskeletal involvement | 32 (16) | 8 (24) | 25 (16) | 17 (34) | 21 (13) | 7 (14) |
| Digital ulcers | 40 (21) | 5 (15) | 20 (13) | 6 (12) | 18 (12) | 5 (10) |
Continuous variables are represented with medians and IQRs, and categorical variables with numbers and percentages.
For females: the following characteristics were significantly different between the cohort-entry groups: age (p=0.006), non-RP duration (p<0.001), diagnosis duration (p<0.001), presence of ACA (p=0.024), cardiac involvement (p=0.007), interstitial lung disease on HRCT (p=0.014) and interstitial lung disease on HRCT and FVC <80% (p=0.049).
For males: the following characteristics were significantly different between the cohort-entry groups: non-RP duration (p=0.012) and diagnosis duration (p=0.023).
ACA, anticentromere autoantibody; FVC, forced vital capacity; HRCT, high-resolution CT; RP, Raynaud’s phenomenon.